A new study of 6,500 patients, published in the April 11 issue of JAMA, shows that losartan, a primary drug for hypertension, is not linked to a higher all-cause death or cardiovascular death, in comparison with ARB candesartan. Observational studies had indicated that losartan was likely to be linked to a higher mortality rate amongst patients with heart failure than other medications in the same class of drugs, such as angiotensin II receptor blockers [ARBs]. Henrik Svanstrom, M.Sc...
More...
More...